Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 days ago

Cabaletta Bio, Inc.: Bain Capital Life Sciences Opportunities III, LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Bain Capital Life Sciences Opportunities III, LP amended its Schedule 13G filing on Cabaletta Bio, Inc., disclosing its updated beneficial ownership stake in the clinical-stage biotechnology company. The amendment was filed with the SEC under accession number 0001193125-26-461980. Schedule 13G amendments are typically filed by passive institutional investors when their ownership position changes, though the filing did not specify the exact size or direction of the stake adjustment. The disclosure matters because large institutional holders like Bain Capital Life Sciences can influence Cabaletta's governance and signal confidence in its autoimmune-focused cell therapy pipeline. Investors will watch for further 13G or 13D filings to confirm whether Bain's position is increasing or being trimmed.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Cabaletta Bio, Inc., Bain Capital Life Sciences Opportunities III, LP